Vaccines are out of my area but I've been around long enough to know that trying to predict when the FDA will bring in an AC is an exercise in frustration.
I know no one will believe me (and personally I don’t care if you do or not), but I’ve been on enough FDA panels to know that this request is about labeling not approvability. They’re simply looking for risk groups to be identified in the product label. Sure, the company is inexperienced and screwed up by submitting aggregate data, but if you sell based on this news you are truly a fool.
Geez, you are kidding, aren't you? Welcome to the 21st century. It's all about electronic banking. Close the branches, cut costs, but keep the customers.
This is all BS. DVAX's product portfolio is mostly outside CELG's area of interest. Rather than these lunatic calls for a buyout, why not just appreciate that this a great small company with a vaccine that's a slam dunk for approval and other interesting products in the pipeline?
Correct. If any killer bad news was leaking there's a lot more leverage in far out of the money puts. And everyone is assuming the put transaction was initiated by the buyer. Does anyone know whether it was done at the bid or at the asked? Maybe it was a put SELLER trying to capture the premium or buy the stock on the cheap.
1. 2000 puts = 200,000 shares. Clearly an institution hedging $5,000,000 worth of stock. The size of the option transaction was so out of whack to previous option activity that it would be a red flag to the SEC if someone was making a spec bet based on “inside info”.
2. Anyone have access to open interest in puts that expired last week? This could have been an institution rolling over their hedge.
3. Apparently a lot of retail investors got shaken out of their positions today based on that put trade. Stock volume was mostly many small trades of a few thousand shares each. Not much liquidity in the market on a holiday week and it doesn’t take much to move a volatile stock like DVAX on a day like this.
4. No trend lines were broken and overall direction is still up.
You are correct. It is basically meaningless. Overall survival and disease-free survival are the key and will not be reported until next year. They do not necessarily correlate with progression-free survival.
If you "don't understand the price action" why are you buying in here? Also, are you aware that the price of the stock will be reduced by any dividends MEMP declares between now and January 2017, so the distance to $10 may be longer than you think.
You guys never learn. It's not about the past it's about the future.They've not replaced their biggest customer (Rabobank) and that contract is almost completed.
Look up the word contango. You're constant buying more expensive futures contract to replace expiring futures contracts that have declined in value over the previous month. Therefore, if the price of oil stays the same, you are guaranteed to lose money. The only way these ETN's make sense is if you buy one day and correctly time a big spike the next day.
Keep your pants on. All the biotechs are in a "buy the rumor, sell the news" mode which was clearly predicable considering the pre-meeting run up.
This is not good news. The President and COO sold 1/3 of his position after last week's quarterly report. Yahoo will not let me post the link, but you can find it by going to the VDSI page on nasdaq.com, and click on "SEC filings" in the left column. When you're on the SEC filings page, it's the 2nd one listed (form type 4).
...and begging for an intelligent, non-sarcastic answer:
Why does the company seem to have difficulty cracking the US market? Is it because the US still uses the old magnetic strip credit cards while the rest of the world is moving to chip on a card? If so, once the US finally moves to chip on a card, it should be a bonanza for VDSI.